title: Dose and load studies for subcutaneous and oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin.
abstract: Poly(lactide-co-glycolide) microspheres containing different loads of OVA (0.05, 0.1, 0.5 and 1.0% w/w) were manufactured by a w/o/w emulsion/solvent evaporation method. Low load efficiencies of less than 20% were observed. Normal size distributions with mean volume diameters ranging from 3.7 to 4.7 microns were obtained for different batches. The in vitro release of OVA from different loaded microspheres showed an expected burst release with all batches. The in vivo dose study (1, 10, 25, 50 micrograms of OVA) was performed by subcutaneous and oral inoculation in mice by single (0 week) or double (0 and 3 weeks) administration of PLGA 50/50 microspheres containing 0.1% OVA. Subcutaneous administration showed an immune response (serum Ig levels by ELISA) statistically (Fisher's paired t-test; P < 0.05) above OVA saline negative controls at 3, 6 and 12 weeks after administration. Oral administration of microspheres produced statistically higher systemic immune responses at the higher doses. Single and double inoculation orally and subcutaneously produced similar serum antibody levels. The in vivo load study was performed by subcutaneous and oral administration to mice of 25 micrograms OVA contained in various loaded (0.05, 0.1, 0.5 and 1.0% w/w) microspheres. Serum immune responses at 3, 6, and 12 weeks after inoculation were statistically above OVA saline controls and were inversely proportional to the OVA load using either route. This observation suggested a relationship between the number of microspheres delivered and the in vivo serum response. Single subcutaneous administration of 0.05 or 0.1% OVA loaded PLGA 50/50 microspheres induced larger immune responses compared with complete Freund's adjuvant.
authors.affiliation: Upjohn Company, Drug Delivery Research and Development, Kalamazoo, Michigan 49001.
authors.forename: T
authors.initials: T
authors.lastname: Uchida
authors.forename: S
authors.initials: S
authors.lastname: Martin
authors.forename: T P
authors.initials: TP
authors.lastname: Foster
authors.forename: R C
authors.initials: RC
authors.lastname: Wardley
authors.forename: S
authors.initials: S
authors.lastname: Grimm
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000906:Antibodies / Q000032:analysis; D002214:Capsules; D003692:Delayed-Action Preparations; D007279:Injections, Subcutaneous; D051379:Mice; D008807:Mice, Inbred BALB C; D008855:Microscopy, Electron, Scanning; D010047:Ovalbumin / Q000008:administration & dosage* / Q000378:metabolism; D011098:Polyglactin 910
chemical_list: D000906:Antibodies; D002214:Capsules; D003692:Delayed-Action Preparations; D011098:Polyglactin 910; D010047:Ovalbumin